Cassava Sciences and its Alzheimer’s drug are done. The damage lingers - STAT

The Cassava Sciences story ended Monday exactly as many knew it would — with the company’s experimental drug for Alzheimer’s disease, simufilam, failing a clinical trial.

By: STAT

Nov 27 2024
0
0 Views

Four years on, the Cassava Sciences story ended Monday exactly as many knew it would with the companys experimental drug for Alzheimers disease, simufilam, proving to be nothing more than a placebo i… [+697 chars]

‘Buy now, pay later’ is more popular than ever. It can cost more than you think - Yahoo Finance

Bird Flu Emerges as Key Reason Behind U.S. Egg Shortage - Gizmodo

Stock Market Today: Dow Jones Up, Yields Fall After Trump Treasury Pick; Berkshire Gains Amid This Key Warren Buffett Move (Live Coverage) - Investor's Business Daily

Kohl's CEO Tom Kingsbury to step down in January, to be replaced by Michaels CEO Ashley Buchanan - CNBC

Gay MSNBC host Jonathan Capehart said he’s ‘conflicted’ by Trump move to pick Scott Bessent for Treasury - New York Post

Tesla Stock Drops. It May Get Excluded From California Tax Credits. - Barron's

Share this page

Guest Posts by Easy Branches

Banner advertising on easybranches network